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 2 
ABSTRACT  28 
Plasmodium falciparum Erythrocyte Membrane Protein 1 (PfEMP1) mediates parasite 29 
sequestration to the cerebral microvasculature via binding of DBL domains to Intercellular 30 
Adhesion Molecule 1 (ICAM1) and is associated with severe cerebral malaria. In a cohort of 187 31 
young children from Papua New Guinea (PNG), we examined baseline antibody levels to the 32 
ICAM1-binding PfEMP1 domain, DBLβ3PF11_0521, in comparison to four control antigens 33 
including NTS-DBL and CIDR1 domains from another group A variant and a group B/C 34 
variant. Antibody levels for the group A antigens were strongly associated with age and 35 
exposure. Antibody responses to DBLβ3PF11_0521 were associated with a 37% reduced risk of 36 
high-density clinical malaria in the follow up period (adjusted incidence risk ratio, aIRR = 0.63 37 
[95% CI: 0.45-0.88; p = 0.007]) and a 25% reduction in risk of low-density clinical malaria 38 
(aIRR = 0.75 [95% CI: 0.55-1.01; p = 0.06]), whilst there was no such association for other 39 
variants. Children who experienced severe malaria also had significantly lower antibody levels to 40 
DBLβ3PF11_0521 and the other group A domains than other children. Furthermore, a subset of PNG 41 
DBL sequences had ICAM1-binding motifs, formed a distinct phylogenetic cluster and were 42 
similar to sequences from other endemic areas. PfEMP1 variants associated with these DBL 43 
were enriched for DC4 and DC13 head-structures implicated in EPCR-binding and severe 44 
malaria, suggesting conservation of dual binding specificity. These results provide further 45 
support for the development of specific classes of PfEMP1 as vaccine candidates, and as 46 
biomarkers for protective immunity against clinical P. falciparum malaria.  47 
Key words. Malaria; var genes; PfEMP1; immunity; DBL; ICAM1  48 
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 3 
BACKGROUND  49 
Malaria due to infection with Plasmodium falciparum remains a major global public health issue, 50 
with more than 400,000 deaths and 215 million symptomatic episodes each year (1). Children 51 
with limited prior exposure to malaria bear the majority of the disease burden, however naturally 52 
acquired immunity eventually develops with age and exposure, and is associated with the 53 
acquisition of a diverse repertoire of antibodies to parasite-encoded variant antigens on the 54 
infected erythrocyte surface (2). The major target of this immunity is P. falciparum Erythrocyte 55 
Membrane Protein 1 (PfEMP1) (3, 4), which is differentially encoded by up to 60 highly 56 
polymorphic var genes per parasite genome (5-7). Expression of diverse PfEMP1/var gene 57 
variants allows clonal antigenic variation (8, 9) and cytoadhesion to a wide variety of host 58 
molecules including chondroitin sulphate A (10), CD36 (11), endothelial protein C receptor 59 
(EPCR) (12) and Intercellular Cytoadhesion Molecule 1 (ICAM1) (13). Adhesion occurs via 60 
specialized PfEMP1 domains, known as Duffy Binding Like (DBL) and Cysteine-rich 61 
Interdomain Region (CIDR) (7). Whilst antibodies to PfEMP1 in general have been shown to be 62 
important mediators of protection against symptomatic malaria, the specific PfEMP1 variants 63 
targeted by protective immune responses are poorly understood. 64 
Var genes have been classified into three major groups (A, B, and C) based on chromosome 65 
orientation and conserved structural and sequence features, and in addition there exists a group of 66 
chimeric genes (B/A), also known as domain cassette (DC) 8 (14). Group A and B/A var genes 67 
are expressed in parasites isolated from children with severe disease and are up-regulated in 68 
cytoadherent parasites linked to pathogenesis (reviewed by(15, 16)). PF11_0521 and PFD1235w 69 
are group A var genes that contain ICAM1-binding DBL domains (17-19). Infected 70 
erythrocytes co-localize with ICAM1 expression in the brain blood vessels suggesting that 71 
ICAM1 mediates parasite sequestration in cerebral malaria (20). These genes also belong to the 72 
subclass of group A PfEMP1 variants that have adjacent CIDR domains that bind EPCR (21), 73 
another important host-parasite interaction implicated in severe malaria (12). Dual binding to 74 
these host receptors has been linked to cerebral malaria (21). To our knowledge, only one study, 75 
conducted in Tanzanian children, has found an association between high levels of antibodies 76 
against the ICAM1-binding DBL domain of PF11_0521 (DBLβ3PF11_0521) and a reduced risk of 77 
severe malaria (22). The role of antibodies against ICAM1-binding DBL in protection against 78 
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 4 
clinical and severe malaria is thus not well understood, and has not been studied outside of sub-79 
Saharan Africa.  80 
 81 
Considering the diverse functional roles of different PfEMP1 variants and domains, protective 82 
immunity would be expected to vary considerably among different PfEMP1 subgroups and 83 
cytoadherent domains. Therefore, this study aimed to investigate whether antibodies against 84 
DBL3PF11_0521 are associated with protection against clinical and severe malaria in comparison 85 
to domains from other PfEMP1 variants not associated with ICAM1-binding or severe malaria 86 
(23, 24). The study was conducted in a longitudinal cohort of very young (aged 1-3 years) 87 
children from Papua New Guinea (PNG) that are actively acquiring immunity to malaria (25), 88 
and to minimize the background of diverse PfEMP1 antibodies that are acquired with high 89 
malaria exposure (25-27). Plasma antibody levels were measured at baseline and associated with 90 
prospective risk of uncomplicated (clinical) and severe malaria. To explore the 91 
PfEMP1landscape of PNG, we also investigated the presence of ICAM1-binding motifs and the 92 
associated domain architecture of var genes among 125 P. falciparum isolates from three distinct 93 
geographic areas. The results support a role for PfEMP1 variants containing ICAM1-binding 94 
DBLβ as targets for protective antimalarial immunity.  95 
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 5 
RESULTS  96 
Group A PfEMP1 domains are serodominant among young PNG children  97 
Baseline plasma samples from a longitudinal cohort of 187 1-3 year old children from the Maprik 98 
area of East Sepik Province, Papua New Guinea followed for 16 months (25) were screened for 99 
antibodies (IgG) to five PfEMP1 domains including the ICAM1-binding DBLβ3PF11_0521, and 100 
four control antigens. These included two domains from a group A variant PF13_0003 which has 101 
a DBL3 domain but does not have an ICAM1 binding motif (see below): NTS-DBL1.6PF13_0003 102 
and CIDRδPF13_0003, and two domains from a group B/C variant PFL1955w: NTS-103 
DBL0.16PFL1955w and CIDR3.4PFL1955w. Amongst the children, seroprevalence was 2.5 to 4-104 
fold higher for the three type A PfEMP1 domains (40.1% for DBLβ3PF11_0521, 27.8% for 105 
CIDRδPF13_0003 and 24.1% for NTS-DBL1.6PF13_0003) than the type B/C domains (11.2% for 106 
NTS-DBL0.16PFL1955w and 10.1% for CIDR3.4PFL1955w domains) (Figure 1A). Pairwise 107 
comparisons of antibody responses to the five domains showed that seropositivity to 108 
DBLβ3PF11_0521 is significantly higher than all the other domains. In addition, seropositivity to 109 
group A domains is significantly higher than the group B domains (Table S1). Similarly, a 110 
combined analysis of seropositivity to any one of the group A PfEMP1 (55%) was significantly 111 
higher than the seropositivity to any one of the group B/C domains (18.7%) after correcting for 112 
multiple comparisons (p = 0.003, Bonferroni adjusted pairwise t-test).  113 
There was a low but significant correlation between antibody responses to DBLβ3PF11_0521 and 114 
NTS-DBL1.6PF13_0003 (Spearman’s rho (rs) = 0.36, p < 0.0001). This was also the case for the 115 
two type A PF13_0003 domains (rs = 0.36, p < 0.0001). In contrast, there was no significant 116 
correlation between the two group B PFL1955w domains (rs = 0.11, p = 0.135), nor between 117 
domains from the different var gene subgroups (Figure 1B). These low but significant 118 
correlations among the group A domains are explained by the predominant expression of and 119 
exposure to type A PfEMP1 variants in early childhood infections (23, 24, 28, 29).  120 
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 6 
Antibodies to five PfEMP1 domains are differentially associated with age and infection 121 
status  122 
To investigate whether past and current exposure to malaria influence responses to the five 123 
PfEMP1 domains, we investigated associations of antibody levels for each of the domains with 124 
age and infection status respectively. Children were split into two groups on the basis of the 125 
median age (1.7yrs) and median antibody responses were compared. Antibody levels were 126 
significantly higher in the older children for group A but not group B/C domains (Figure 2A). 127 
Therefore, the older children had more past exposure to group A antigens than younger children, 128 
whereas group B/C domains were similarly recognized irrespective of age. Concurrent 129 
microscopic parasitemia (median = 3349 parasites/uL) at the time of antibody measurement was 130 
associated with significantly higher antibody levels as compared to the non-infected individuals 131 
for all domains except group B NTS-DBL0.16PFL1955w (p = 0.94, Wilcoxon rank-sum test) 132 
(Figure 2B), which was poorly reactive overall. Children who were infected at enrollment were 133 
3.43 times more likely to be seropositive to at least one of the five PfEMP1 domains than non-134 
infected children [Range: 1.6, 7.8, p = 0.002]. Therefore, current infection appears to boost 135 
antibody levels for all antigens across the cohort.  136 
Antibodies to DBLβ3PF11_0521 but not other domains are associated with reduced risk of high 137 
density clinical malaria  138 
To examine whether antibody responses against any of the domains were associated with 139 
protection against clinical malaria, we conducted a prospective analysis of risk of febrile episodes 140 
and antibody responses. Associations between plasma antibody levels and subsequent risk of 141 
symptomatic malaria (all clinical episodes (fever and ≥2500 parasites/μl) and high density 142 
clinical malaria (fever and ≥10000 parasites/μl)), were determined by grouping individuals into 143 
tertiles, and comparing high and low antibody groups. An important feature of the analysis is the 144 
adjustment for confounding variables at the individual level such as the molecular force of blood 145 
stage infection (molFOB, see Materials and Methods). Children with high levels of antibodies to 146 
DBLβ3PF11_0521 had a 37% reduction in risk of high-density clinical malaria that was highly 147 
significant (febrile illness with ≥10000 parasites/μl: adjusted incidence rate ratio (aIRR) = 0.63 148 
[95% CI: 0.45-0.88; p = 0.007]) and a 25% reduced risk of clinical malaria that was borderline 149 
significant (febrile illness with ≥2500 parasites/μl: (aIRR) = 0.75 [95% CI: 0.55-1.01; p = 0.06]). 150 
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 7 
However, there was no significant reduction in risk in either presentation of clinical malaria for 151 
the other four domains tested (Figure 3). 152 
Children that developed severe malaria had significantly lower antibodies to DBLβ3PF11_0521 153 
Having determined that antibody responses to DBLβ3PF11_0521 were associated with protection 154 
against clinical malaria, and in particular high-density clinical malaria, a biomarker for severe 155 
disease, we then wanted to examine antibody responses in the children that experienced severe 156 
disease in the follow-up period. According to WHO criteria (31), of the 187 children, 18 157 
experienced severe P. falciparum malaria during the follow-up period ((25), Table S2). On 158 
average, these children were similar to those that did not develop severe malaria with respect to 159 
age (Severe cases: 1.64 yrs vs Non-severe cases: 1.89 yrs, p = 0.12) and exposure, experiencing a 160 
similar number of distinct P. falciparum infections during the follow-up period (Severe: 5.19 and 161 
non-severe: 5.17, p = 0.98). However, children who experienced severe malaria had significantly 162 
lower antibodies to DBLβ3PF11_0521 at baseline than those that did not develop severe malaria 163 
(Figure 4, p = 0.004). Children who developed severe malaria also had significantly lower 164 
antibodies to the other type A PfEMP1 domains (p < 0.01) and the type B/C domain 165 
CIDR3.4PFL1955w (p = 0.024). For the NTS-DBL0.16PFL1955w domain with low reactivity, there 166 
was no significant difference (p = 0.95, Figure 4). 167 
PNG PfEMP1 with ICAM1-binding DBL domains are enriched for DC4 and 13  168 
The PF11_0521 PfEMP1 variant is from 3D7, an isolate with possible African origin and dual-169 
binding activity with ICAM1 (via DBL) and EPCR (via DC13,(21)). Previous studies 170 
investigating dual ICAM1-EPCR binding have focused on collections of reference strains or field 171 
isolates from different geographic areas (21, 32). To determine whether PNG isolates possess 172 
ICAM-binding motifs and to study the associated PfEMP1 domain architecture, we conducted a 173 
detailed analysis of var genes extracted from whole genome sequence data of 125 P. falciparum 174 
isolates from PNG. Among the genomes we identified 4044 full or partial ORF’s that were 175 
classified as var genes using BLAST against a database of classified DBL and CIDR domains 176 
(mean no. distinct PfEMP1 per genome =32, range = 1-60, mean coverage =33 reads, range = 8-177 
124 reads, Supporting File: Table S3). Of those, 117 genomes contained 1505 DBLdomains 178 
with a mean coverage of 35 reads distributed among 1420 var genes (i.e. many var genes had 179 
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 8 
multiple DBL domains). For the 8 PNG genomes without DBL domains, 6 had low coverage 180 
resulting in poor sampling of var genes (n=1-6), whilst two isolates had higher coverage and 181 
contained 12 and 21 var genes. Among 1505 PNG DBL sequences (Supporting File: Table S3, 182 
Dataset 1), 81 contained the ICAM1-binding motif (21). They included 47 DBL1 (58%), 33 183 
DBL3 (41%) and 1 DBL7 (1%) that were distributed among 61 genomes, and 80 var genes (1 184 
var gene had two ICAM1 binding motifs: DBL1 and DBL7) (Supporting File: Table S4). To 185 
examine PNG DBLdiversity in context with parasite populations of other malaria endemic 186 
countries, 279 DBL sequences from other countries and reference isolates including 187 
DBLβ3PF11_0521 (linked to DC13) and DBLβ3PFD1235w (another ICAM1 binding variant linked to 188 
DC4, (18, 19)) were included in the analysis (Supporting File: Dataset 2). Of these, 22 contained 189 
the ICAM1-binding motif and they were found within 11 DBL1 (50%) and 11 DBL3 (50%) 190 
domains (Supporting File: Table S5). All DBL1 and 3 from both datasets (406 PNG + 178 191 
other, Datasets 1 and 2) were then combined for multiple alignment. Truncated sequences were 192 
removed resulting in 455 sequences, including 102 with the ICAM1 motif. Phylogenetic analysis 193 
of the SD3 region encompassing the ICAM1-binding motif, revealed an “ICAM1-binding” 194 
cluster populated entirely by DBL with the ICAM1-binding motif (Figure 5A). The average 195 
evolutionary distance of the DBL predicted to bind ICAM1 was 0.532 compared to 1.011 for 196 
the remaining DBL. PNG DBL sequences were distributed throughout the tree, and there was 197 
no evidence of population structure. Of note, PF13_0003 contains a DBL sequence, however it 198 
did not contain an ICAM1-binding motif and was divergent to sequences in the ICAM1-binding 199 
clade (Figure 5A). These results suggest that the majority of PNG parasites carry at least one 200 
PfEMP1 with predicted ICAM1-binding. 201 
To determine the PfEMP1 context of DBLwith predicted ICAM1 binding, we investigated the 202 
domain architecture of full-length var gene assemblies from the PNG genomic sequence data 203 
with respect to adjacent domains and specific DC classes. All PNG PfEMP1 sequences with 204 
DBL1 and 3 domains contained CIDR1 domains (EPCR-binding). However, PfEMP1 205 
containing DBL domains with the ICAM1 motif (n=80, Tables S3,4) were significantly 206 
enriched for adjacent DC13 structures (46.3% compared to 20.5% among PfEMP1 with DBL 207 
domains with no motif, p<0.0001, Binomial Exact Test) and DC4 (13.8% compared to 6.0%, 208 
p=0.008, Binomial Exact Test) (Figure 5B, Supporting File: Table S6), which are strongly 209 
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 9 
associated with severe malaria and dual EPCR/ICAM1-binding (21, 32). In the phylogenetic 210 
analysis, DBL with adjacent DC4 and DC13 were divergent, although several DBLassociated 211 
with DC4 were identical, suggesting conservation of a common var gene (Figure S2). Other DC 212 
structures including DC8, DC16 and DC1-var1 were not found amongst the PfEMP1 with the 213 
ICAM1 binding motif (Figure 5B). This suggests that specific classes of PfEMP1 with dual 214 
binding specificity to ICAM1 and EPCR are maintained in PNG isolates, confirming previous 215 
observations in African isolates (21).  216 
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 10 
DISCUSSION  217 
 218 
PF11_0521 belongs to a class of group A PFEMP1 with DBL domains shown to bind ICAM1, 219 
and found exclusively in PfEMP1 with EPCR-binding CIDR1 (16, 35). These domains are 220 
adjacent to each other and together they may produce a binding phenotype often associated with 221 
sequestration leading to cerebral malaria (13, 18-21, 32). Our results support a role for these 222 
PfEMP1 in clinical and severe malaria in young children by demonstrating that (i) antibodies 223 
against DBLβ3PF11_0521 are significantly associated with protection against high-density clinical 224 
malaria, (ii) children that developed severe malaria had lower levels of antibodies  to 225 
DBLβ3PF11_0521 prior to the disease episode (albeit antibodies to other antigens were also lacking 226 
in these children), (iii) there are ICAM1-binding motifs present in DBL sequences from PNG 227 
isolates, and (iv) PfEMP1/var genes with predicted ICAM1-binding are also predicted to bind 228 
EPCR (21, 32).  229 
The cohort of 1-3 year old PNG children was specifically chosen to explore early antibody 230 
responses to PfEMP1, because their immunity to malaria was incomplete (25) and to limit the 231 
complex background antibody responses that are observed in older children and adults (27). 232 
Antibodies to PfEMP1 domains were associated with age and current infection in the cohort, 233 
consistent with exposure driving the acquisition and maintenance of immunity to malaria (2). In 234 
addition to the measurement of exposure to new infections in the follow up period (molFOB), 235 
these results provided a basis for exploring associations with the risk of disease adjusted for 236 
important confounding factors (33). Because the number of severe disease cases was small 237 
(n=18), we initially focused the prospective risk analysis on clinical infections, which occurred at 238 
a high rate in these children (25). High density clinical malaria (fever plus ≥10,000 parasites/L) 239 
is considered a surrogate marker for severe disease since these children have intense infections, 240 
yet are not classified into any of the severe disease syndromes by WHO criteria (31). The 241 
significant reduction in risk of these high density clinical infections if children had high levels of 242 
DBLβ3PF11_0521 antibodies, suggests that inhibition of ICAM1-binding or other binding phenotype 243 
by antibodies against these PfEMP1 may limit parasite burden and progression to severe malaria. 244 
Antibodies to DBLβ3PF11_0521 have previously been associated with a reduced risk of 245 
hospitalization with severe or moderately severe malaria in Tanzanian children (22), clearly 246 
demonstrating potentially protective immune response associated with exposure to PfEMP1 with 247 
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 11 
DBLβ3PF11_0521-like variants. Tanzanian children with high antibody reactivity to CIDRα1 from 248 
the other confirmed ICAM1-binding protein, PFD1235w, also had a lower risk of anemia 249 
(hemoglobin <11 g/dL) and clinical malaria (34). Furthermore, ICAM1-binding inhibitory 250 
antibodies are common in hyper-immune adults living in endemic areas (19) suggesting that they 251 
may play an important role in the maintenance of clinical immunity. The mechanism of 252 
protection may be through direct inhibition of ICAM1-binding as shown in vitro experiments (21, 253 
35), indirectly, through prevention of binding of other domains, such as EPCR-binding CIDR1 254 
(12), or synergistic antibody responses targeting multiple domains.  255 
Whilst a broad repertoire of PfEMP1 antibodies was acquired in these young children, only 256 
antibodies against the ICAM1-binding full-length DBL3 PF11_0521 domain were associated with 257 
protection against both clinical and severe malaria. The results are strengthened by fact that 258 
children also acquired antibodies to domains from the other group A PfEMP1 variants tested in 259 
this study (NTS-DBL1.6PF13_0003 and CIDRδPF13_0003), yet they were not associated with a 260 
reduced risk of clinical malaria. The higher recognition of group A antigens in the children 261 
overall, and the significantly higher recognition in older children for group A, but not group B/C 262 
antigens, suggests shared epitopes within this group of PfEMP1 variants and confirms a hierarchy 263 
of PfEMP1 exposure with age (27-30). One caveat to mention is the use of different assays for 264 
DBLβ3PF11_0521 and the control antigens, which prevented the direct comparison of antibody units 265 
between antigens. However, the prospective risk analyses and comparison between groups were 266 
done for each antigen independently, thus limiting potential biases of the different assays. 267 
Another limitation of this study is the small number of PfEMP1 proteins and the lack of a direct 268 
comparison of DBLβ3PF11_0521 with other non-ICAM1 binding DBLβ domains. Parallel analyses 269 
of antibody responses to a large panel and variety of PfEMP1 domains will be a valuable 270 
extension of this study. 271 
Dissecting the association of antibodies to different parasite antigens with protection and 272 
exposure is important in understanding naturally acquired immunity to malaria (33). In the same 273 
cohort, high levels of antibodies to merozoite antigens were predictive of an increased risk of 274 
developing clinical malaria (33). In older PNG children aged 5-14 years however, antibodies 275 
against merozoite antigens were found to be associated with protection against clinical malaria 276 
(33). Therefore, merozoite antigens are biomarkers of accumulated malaria exposure in the 277 
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 12 
younger age group, however with increasing exposure and responses of higher magnitude, 278 
antibodies to merozoite antigens become biomarkers of protective immunity (33). We used the 279 
molFOB as a marker of exposure at an individual level to adjust for the confounding effects of 280 
exposure in the prospective risk analysis (26, 33). We observed significant protection against 281 
clinical malaria in children with high levels of DBLβ3PF11_0521 antibodies despite these differing 282 
exposures to malaria. That is, children who had antibodies to DBLβ3PF11_0521 had lower rates of 283 
clinical malaria than those who had low levels of these antibodies, even after adjusting for 284 
individual differences in the rate of new malaria infections.  285 
We also found an association between the lack of antibodies to DBLβ3PF11_0521 and other group A 286 
PfEMP1 domains and the prospective risk of severe malaria, however in this analysis we also 287 
found associations with other antigens. Children who experienced only uncomplicated or 288 
asymptomatic malaria had significantly higher levels of antibodies to all three group A antigens 289 
and one of the group B antigens than children who developed severe malaria in the follow up 290 
period. Taken together the observed association of antibodies to DBLβ3PF11_0521 with reduced 291 
risk of high density clinical malaria and severe malaria suggests epitopes in DBLβ3PF11_0521–like 292 
sequences or adjacent PfEMP1 domains may be important targets of protective immunity. 293 
The association with other domains in severe malaria may be due to the fact that we did not 294 
adjust for confounders and is also consistent with the early acquisition (and potential 295 
protective effects) of antibody responses to group A antigens compared to B antigens 296 
(27,28,30). However, we cannot rule out that other domains tested are important targets of 297 
protection against severe malaria. 298 
The importance of host-parasite interactions via ICAM1 to the PNG parasite population is 299 
indicated by the maintenance of a class of relatively conserved DBL sequences with predicted 300 
ICAM1-binding (18, 21). Phylogenetic analysis of the C-terminal DBL subdomain 3 (SD3) 301 
domain of DBLβ sequences extracted from 125 parasite genomes of PNG together with those 302 
of geographically diverse isolates identified a cluster of sequences previously shown (19, 21) 303 
or predicted to bind ICAM1 as distinguished by a common sequence motif (21). Our data 304 
suggests that similar subsets of group A PfEMP1 with ICAM1-binding DBLβ are found in 305 
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PNG parasites. The lower diversity of this group of sequences compared to other non-ICAM1 306 
binding DBL1/3 suggests positive selection due to functional specialization for binding to 307 
ICAM1. We also found that DBLβ domains with ICAM1-binding motifs are located adjacent 308 
to domain cassettes associated with EPCR binding and severe disease (DC13 and DC4)(18, 20, 309 
21). This assemblage is predicted to confer a dual binding phenotype that has been associated 310 
with severe malaria (12, 21). These results are consistent with the conservation of these 311 
specialized classes of PfEMP1 across large geographic distances since previous studies have 312 
focused on African parasites or reference isolates from diverse locations (18, 21, 32). The high 313 
reactivity of children’s sera to the full-length DBLβPF11_0521 supports the notion that conserved 314 
epitopes exist that can be targeted by cross-reactive and protective antibodies (18, 21, 35). 315 
However, the ICAM1-binding motif is located in C-terminal part of the protein (SD3 region), 316 
and no sequence traits in the N-terminal part of the domain have been linked to ICAM1 317 
binding. The protective association may therefore be accounted for by epitopes outside the 318 
SD3 region or as a result of its concurrence with other virulence-associated domains in the 319 
same PfEMP1.  320 
Our analysis of antibodies to functionally diverse PfEMP1 domains extends previous insights 321 
into early exposure to PfEMP1 (22, 27, 28, 30), revealing that young children from PNG are 322 
highly exposed to group A antigens whilst having limited exposure to group B/C antigens. The 323 
finding that high levels of antibodies against DBLβ3PF11_0521 are associated with a reduced risk of 324 
high-density clinical and severe malaria supports a role for PfEMP1 in malaria pathogenesis via 325 
ICAM1-binding domains or adhesion of adjacent domains. The demonstration that PNG P. 326 
falciparum isolates contain PfEMP1/var genes with predicted ICAM1-binding closely linked to 327 
predicted EPCR-binding CIDR domains suggests positive selection and functional specialization 328 
of a subclass of dual binding PfEMP1 implicated in severe malaria syndromes. Studies 329 
investigating whether antibodies in clinically immune children interrupt binding interactions 330 
between ICAM1 and this class of DBLβ sequences would establish a more direct link to 331 
protection against malaria. Antibodies to the EPCR-binding CIDR1 domains co-occurring with 332 
ICAM1-binding DBLβ may have synergistic protective effects, however this is yet to be 333 
established. This study adds to the growing body of evidence supporting the development of 334 
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specific classes of PfEMP1 as vaccine candidates. Furthermore, it suggests that this class of 335 
DBL domain could be used as diagnostic antigens to track population immunity during malaria 336 
elimination. 337 
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MATERIALS AND METHODS 338 
Cohort study design 339 
Plasma samples were collected during a longitudinal cohort survey conducted in the East Sepik 340 
Province of PNG. A detailed description of the study is published elsewhere (25, 26). Briefly, 341 
190 children aged 1–3 yrs were enrolled at the start of the study in March 2006 and 74 additional 342 
children were enrolled over the following six months. Children were followed for 69 weeks with 343 
active and passive follow-up (25). Children were visited fortnightly with collection of 2 blood 344 
samples 24 hours apart for active detection of malaria infection every 8-9 weeks. The 345 
demographic and clinical characteristics of the study population and incidence of clinical malaria 346 
and severe malaria in each 8–9 week follow-up interval have been described in detail elsewhere 347 
(25, 26). Antibody assays were performed on plasma samples collected from 187 (of the 190) 348 
children enrolled in March 2006. Of the 187 children, 48 (25.6%) were microscopy positive for 349 
P. falciparum. The average molFOB in this subset of the cohort was 5.2 and the average number 350 
of clinical episodes was 2 per child per year at risk (25, 26). P. falciparum clinical episodes were 351 
defined as febrile illness (axillary temperature ≥37.5°C or history of fever in the preceding 48hrs) 352 
and >2500 parasites/µl. A high-density clinical episode was defined as febrile illness and >10,000 353 
parasites/µl. Characteristics of children with severe malaria are summarized in Table S2. Written 354 
informed consent was obtained before enrolment of each child. Ethical approval for the study was 355 
granted from the PNG Institute of Medical Research (10.21), the Medical Research Advisory 356 
Council of PNG (10.55) and the Walter and Eliza Hall Institute of Medical Research (11.03).  357 
Protein expression, purification and refolding 358 
DBLβ3PF11_0521 (also known as DBL2βPF11_0521) was expressed, purified and refolded as described 359 
previously (17). As control PfEMP1 proteins without ICAM1 binding activity, we selected NTS-360 
DBL and CIDR domains of two var genes of 3D7: PF13_0003 is a group A PfEMP1 that has 361 
been associated with the formation of rosettes, a phenotype linked with severe malaria (36). In 362 
contrast, PFL1955w is a group B/C PfEMP1 with limited antibodies acquired in young children 363 
(36). The sequences of all five domains are available in the Supporting Materials (Text S1).  364 
NTS-DBL1.6PF13_0003, CIDRδPF13_0003, NTS-DBL0.16PFL1955w and CIDR3.4PFL1955w codon-365 
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optimized sequences were synthesized for E. coli expression (GeneArt). The GenBank accession 366 
numbers are PF13_0003 (XM_001349704) and PFL1955w (XM_001350761). Sequences were 367 
excised from the supplier's vector using BamHI and XhoI and ligated into the pProExHTb 368 
expression vector (Invitrogen), which incorporates an N-terminal hexahistidine fusion tag. The 369 
vectors were then transformed into E. coli strain BL21 (DE3) for expression as described 370 
previously (37). Briefly, the transformed cultures were grown in super broth and expression was 371 
induced with 1mm isopropyl 1-thio-β-D-galactopyranoside, and cultures were grown for a further 372 
3 h at 37 °C. The cells were harvested by centrifugation and lysed by sonication and processed 373 
either as insoluble inclusion bodies (NTS-DBL1.6PF13_0003, CIDRδPF13_0003 and NTS-374 
DBL0.16PFL1955w) or soluble proteins (CIDR3.4PFL1955w). 375 
NTS-DBL1.6PF13_0003, CIDRδPF13_0003 and NTS-DBL0.16PFL1955w proteins were deposited as 376 
insoluble inclusion bodies. Cells were lysed by sonication, and the inclusion bodies solubilized 377 
by the addition of 6M guanidine HCl, pH 8.0. The solubilized proteins were purified by metal-378 
chelating chromatography using a nickel-nitrilotriacetic acid (Ni-NTA) column (Qiagen) under 379 
reducing conditions. Optimum refolding conditions were determined for each protein. The 380 
NiNTA eluted CIDRα3.4PFL1955w and the refolded CIDRδPF13_0003 proteins were purified using 381 
strong anion-exchange chromatography. Proteins were eluted from Hitrap Q column (GE 382 
Healthcare) and the relevant fractions were pooled and concentrated. For CIDRα3.4PFL1955w, the 383 
protein was further purified by size exclusion chromatography. The refolded NTS-384 
DBL1.6PF13_0003 and NTS-DBLα0.16PFL1955w domains were further purified using cation-385 
exchange chromatography. Bound proteins were eluted from a Hitrap SP column (GE 386 
Healthcare) and the relevant fractions were pooled, concentrated and further purified by size 387 
exclusion chromatography. The purity of each protein was assessed on SDS-PAGE gels and via 388 
western immunoblots using standard conditions. Briefly, proteins were run on a 4–12% Bis-Tris 389 
SDS-PAGE (Invitrogen). Standard Western blotting procedures were performed for non-reduced 390 
and reduced (by addition of β-mercaptoethanol) samples using nitrocellulose and the 391 
immunoblots were processed with enhanced chemiluminescence (ECL) substrates (GE 392 
Healthcare). For all Western blots, recombinant proteins were detected with pooled hyperimmune 393 
sera from highly exposed PNG adults (see Supplementary figure 1). A single batch of each 394 
protein was used for all serological screening. The purified proteins were assessed using a pool of 395 
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hyperimmune plasma (see Supplementary Figure 1) and a single batch of each protein was used 396 
for all serological screening. 397 
Measurement of antibody responses 398 
Plasma samples collected at enrolment (n = 187) were tested for antibodies comprising total 399 
Immunoglobulin G (IgG) to DBLβ3PF11_0521 using a standard ELISA assay. For the other four 400 
domains, IgG levels were measured using the cytometric bead array (CBA) as described 401 
previously (38). The details are described below. 402 
ELISAs were performed to measure total IgG using standard methods. Ninety-six well plates 403 
(Nunc, Denmark) were coated with 1μg/ml of DBLβ3PF11_0521 recombinant protein in PBS and 404 
incubated overnight at 4°C. PBS with 5% skim milk was used for blocking and PBS with 1% 405 
skim milk and 0.05% tween for diluting the plasma samples and antibodies. Plasma was added at 406 
1 in 100 dilutions. For measurement of total IgG, horseradish peroxidase-conjugated mouse anti-407 
human IgG (SouthernBiotech, USA) was used at a dilution of 1 in 1000. Finally, TMB microwell 408 
peroxidase substrate (KPL, Inc., Australia) was added, and the reaction was stopped using 1M 409 
H3PO4 and the optical density (OD) was measured at 450 nm. All samples were tested in 410 
duplicate. Background (determined from the wells with no plasma) was deducted and the 411 
threshold for a seropositive response was determined using reactivities of 1:100 diluted plasma 412 
samples from anonymous malaria-naïve Australian adults (n=12). The mean value among these 413 
negative control plasma samples plus 3SD was used as a cut-off value to define seropositivity.  414 
CBAs were carried out using four micro-beads (BD Bioscience, San Diego, CA, USA) of distinct 415 
and non-overlapping fluorescence intensities covalently coupled to NTS-DBL1PF13_0003, 416 
CIDRδPF13_0003, NTS-DBL0.16PFL1955w and CIDR3.4PFL1955w recombinant proteins according to 417 
the manufacturer's protocol. Briefly, 150μl of selected micro-beads were sonicated for 1 min and 418 
incubated with 3.8µl of 1M Dithiothreitol (DTT) for 1h at room temperature with agitation. The 419 
beads were washed 3 times and resuspended in 40 µl of coupling buffer (BD Bioscience). 420 
Recombinant proteins (1mg/ml concentration) were activated by incubating with 4µl of 421 
sulfosuccinimidyl 4-N-maleimidomethyl cyclohexane 1-carboxylate (2 mg/ml) for 1h. The 422 
protein mixture was then run through a buffer exchange spin column (Bio-Rad) pre-equilibrated 423 
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with the coupling buffer (BD Bioscience). The activated protein was added to the washed micro-424 
beads and allowed to conjugate for 1h at room temperature with agitation. Four µl of N-425 
Ethylmaleimide (2 mg/ml) was added and the mixture was incubated for another 15 min. The 426 
conjugated micro-beads were then washed, resuspended in 1 ml of storage buffer (BD 427 
Bioscience) and kept at 4°C in the dark. For assessment of antibody responses, 1µl of conjugated 428 
micro-beads was diluted in 50 µl of washing buffer (BD Bioscience) containing 1 in 100 429 
dilutions of plasma samples. Duplicate samples were then incubated for 1hr at room temperature 430 
in the dark, washed and further incubated with mouse anti-human IgG phycoerythrin (PE) 431 
conjugated antibody (BD, Bioscience) for 1hr at room temperature. After washing, the samples 432 
were re-suspended in diluent buffer containing PE (BD Bioscience) and acquired using an LSR 433 
Fortessa analyzer (Becton Dickinson, New Jersey, USA). Analysis was performed using FlowJo 434 
software and the median fluorescence intensity (MFI) for each bead (recombinant protein) was 435 
calculated. Background (determined from the unconjugated beads with plasma samples and 436 
conjugated beads with no plasma samples) was deducted from the mean of each sample. The 437 
threshold for a seropositive response was determined using reactivities of 1:100 diluted plasma 438 
samples from anonymous malaria-naïve Australian adults (n=12). The mean value among these 439 
negative control plasma samples plus 3SD was considered seropositive. The analysis was done 440 
independently for each antigen. 441 
A serial dilution of plasma samples from a pool of hyperimmune PNG adults were included in 442 
each plate to determine standard curves, which was later fitted using a 5-parameter logistic 443 
regression model (Giraldo J, Vivas, NM et al. 2002 Pharmacol Ther) to transform antibody 444 
measured by the two assays into relative antibody units and correct plate-to-plate variations 445 
within an assay.  446 
Statistical Analysis 447 
Statistical analyses were performed using STATA version 12.1 software (Stata Corporation, 448 
USA). Differences in median antibody levels by age and P. falciparum infection status were 449 
compared using the Wilcoxon rank-sum test. The proportions of seropositive children to different 450 
domains were compared using Chi-square tests. Correlation coefficients for antibody levels were 451 
determined using Pearson’s correlation.  452 
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Analyses of the cohort data showed significant over-dispersion in the number of clinical episodes 453 
per child (25), as a result a negative binomial model with generalized estimating equations (GEE) 454 
(based on an XTNBREG procedure) with an exchangeable correlation structure and a semi-455 
robust variance estimator was used for the analyses of association of antibody levels and 456 
incidence of clinical (fever with ≥ 2500 parasites/µl) and high-density clinical episode (febrile 457 
illness and ≥ 10,000 parasites/µl) during the follow-up period. Antibody levels were grouped into 458 
tertiles (low, medium, and high responses) and their association with clinical and high-density 459 
clinical episode was assessed by univariate analyses adjusted for seasonal variation, village of 460 
residence, age at the time of enrollment, P. falciparum infection status and individual exposure as 461 
measured by the molFOB. The molFOB is the number of genetically distinct P. falciparum clones 462 
(based on msp2 genotyping) each child acquired per year at risk (26).  463 
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Sequence Analyses  465 
To identify ICAM1-binding DBL domains and corresponding full length PfEMP1 sequences in 466 
the PNG parasite population, we extracted var gene sequences from the genomes of 125 clinical 467 
P. falciparum isolates collected from three distinct geographic areas of PNG. These isolates were 468 
sequenced as part of the MalariaGEN Community Project (European Nucleotide Archive (ENA) 469 
accession numbers listed in the Supporting File: Table S3). Illumina® short read data sequences 470 
were assembled using Velvet version 1.2.03 (39). Open reading frames were extracted using 471 
Virtual Ribosome ORF finder (40) and var gene-encoded PfEMP1 domain sequences were 472 
extracted from these by BLAST using a library of previously annotated PfEMP1 domain 473 
sequences from 7 reference genomes and classified into subgroups as previously described (41). 474 
All DBL domains were extracted from the PNG dataset (n=1505, Supporting File: Dataset 1), 475 
and complimented with a supplementary dataset from 226 assembled genomes sequenced in the 476 
MalariaGEN Community Project (42) and seven reference genomes (41), including confirmed 477 
ICAM1-binding DBL domains of PF11_0521 and PFD1235w (18) (n=279, Supporting File: 478 
Dataset 2). DBLsequences were screened for a relaxed version of the ICAM1 motif: N-G-G-479 
[PA]-x-Y-x(27)-G-P-P-x(3)-H (21) using the web-based server Scan Prosite (43). All sequences 480 
from the DBL classes with ICAM1-binding motifs (DBL1 and DBL3) were aligned using 481 
Muscle with default settings in MEGA version 7.0 (37). After removing truncated sequences 482 
(n=40), and focusing on the S3 region of DBLwhich contains the ICAM1 binding motif (21), 483 
we then conducted a phylogenetic analysis using a total of 367 PNG DBLβ1 and DBL3 484 
sequences originating from PNG isolates together with 89 DBLβ1 and DBL3 sequences from 485 
the supplementary dataset. A maximum likelihood tree was estimated using the JTT substitution 486 
model with 1000 bootstrap repetitions in MEGA version 7.0 (44). We measured the average 487 
evolutionary divergence among sequences using the Dayhoff model in MEGA version 7.0 (44). 488 
In addition, we characterized the domain architecture of PfEMP1 with DBL1 and DBL3 489 
domains by extracting the domain classifications from the BLAST output (Supporting File: Table 490 
S6). We then assessed whether the frequency of each domain cassette amongst the ICAM1-motif 491 
containing sequences varied significantly from the expected frequency (among a subset of 331 492 
PfEMP1 with DBL1/3 domains) using an Exact Binomial test using R software (45). 493 
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 676 
FIGURE LEGENDS 677 
Figure 1. Antibody responses to five PfEMP1 domains in 187 young Papua New Guinean 678 
children. A. Domain composition and seroprevalence of the five tested PfEMP1 domains. 679 
Seroprevalence is indicated in percentage above the relevant domains. B. Correlation coefficients 680 
for seropositivity to five PfEMP1 domains. Significant correlations (p < 0.001) are indicated by 681 
the asterisk. 682 
 o
n
 M
ay 29, 2018 by TECH KNO
W
LEDG
E CTR O
F DENM
ARK
http://iai.asm
.org/
D
ow
nloaded from
 
 27 
Figure 2. Relationship between antibody responses to five PfEMP1 domains, age and 683 
infection status. A. IgG levels stratified by age (age groups determined by the median age (1.7 684 
years)). B. IgG levels stratified by P. falciparum infection status. In both panel, box and whisker 685 
plots for the relative antibody units (in log10) are shown for the five PfEMP1 domains. Boxes 686 
show the interquartile range, midline is the median, whiskers the 95% confidence interval and 687 
dots are the outliers (95–99%). P-values for the differences were determined using the Wilcoxon 688 
rank-sum test between the groups. 689 
Figure 3. Antibody responses to five PfEMP1 domains and prospective risk of symptomatic 690 
malaria. Antibody levels were grouped into three equal groups (High, Medium and Low). The 691 
incidence rate of clinical malaria and high-density clinical malaria were compared for high and 692 
low responders for each tested domain using negative binomial regression. The incidence rate 693 
ratios were adjusted for villages of residence, seasonal variation, age (continuous), infection 694 
status at the time of antibody measurement and differences in individual exposure (molFOB). 695 
Adjusted incidence rate ratio (aIRR) for the comparison of high and low responders and the 95% 696 
confidence intervals are shown. The p-values are indicated only when it is significant (p<0.05). 697 
Figure 4. Antibody response to five PfEMP1 domains and development of severe malaria. 698 
Mean and standard error of the relative antibody units are shown for children who experienced 699 
severe malaria (red, n=18) and those who did not (black, n=169). P-values for t-test comparisons 700 
of the means are indicated for each domain.  701 
Figure 5. Conservation of ICAM1 binding motifs and dual EPCR-ICAM1 binding cassettes 702 
in Papua New Guinea. Var gene sequences were assembled for 125 P. falciparum isolates of 703 
Papua New Guinea and domains classified as previously described (41). (A) Maximum 704 
Likelihood tree of 473 DBL1 and DBL3 sequences including 406 from PNG (pink = DBL1, 705 
red = DBL3) and 67 from isolates from diverse geographic locations (cyan = DBL1, blue = 706 
DBL3). Sequences containing the minimal ICAM1-binding motif are indicated by solid circles. 707 
Gene Ids described in this study are indicated against the DBL1/3 variant position in the tree. 708 
(B) Domain architecture of PNG var genes containing DBL1/3 domains with ICAM1 motifs. 709 
The presence of domain cassettes (DCs) among the 80 var genes containing DBL1/3 with the 710 
 o
n
 M
ay 29, 2018 by TECH KNO
W
LEDG
E CTR O
F DENM
ARK
http://iai.asm
.org/
D
ow
nloaded from
 
 28 
ICAM1 binding motif, relative to that among a subset of 331 PNG var genes containing any 711 
DBL1/3, is indicated on the right. Significance was determined by Binomial Exact test. 712 
  713 
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